BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37022724)

  • 1. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.
    Ju N; Hou L; Song H; Qiu Z; Wang Y; Sun Z; Luo Q; Shen C
    Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37022724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients.
    Xiao J; Yun C; Cao J; Ding S; Shao C; Wang L; Huang F; Jia H
    Sci Rep; 2021 Jan; 11(1):1348. PubMed ID: 33446744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
    Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
    J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
    Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy.
    Ju Y; Wang L; Cheng F; Huang F; Chen X; Song Q; Xiao J; Zhu X; Jia H
    BMC Endocr Disord; 2023 Jan; 23(1):19. PubMed ID: 36670396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
    Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER.
    Matrone A; Gambale C; Torregrossa L; Piaggi P; Bianchi F; Valerio L; Viola D; Agate L; Molinaro E; Materazzi G; Basolo F; Vitti P; Elisei R
    Endocr Pract; 2020 Jan; 26(1):58-71. PubMed ID: 31557080
    [No Abstract]   [Full Text] [Related]  

  • 14. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
    Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
    Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
    Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
    Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
    Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.